KU 046
Alternative Names: KU-046Latest Information Update: 21 Mar 2023
At a glance
- Originator Kareus Therapeutics
- Class Antidementias; Small molecules
- Mechanism of Action Reactive oxygen species inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Fragile X syndrome; Multiple sclerosis
Most Recent Events
- 21 Mar 2023 Discontinued - Phase-I for Alzheimer's disease (In volunteers) in USA (PO)
- 21 Mar 2023 Discontinued - Preclinical for Fragile X syndrome in Switzerland (PO)
- 21 Mar 2023 Discontinued - Preclinical for Multiple sclerosis in Switzerland (PO)